Slingshot members are tracking this event:

Amgen (AMGN) Announces Top-Line Results From Phase 3 KYPROLIS (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details  Amgen announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS (carfilzomib), melphalan and prednisone (KMP) versus Velcade (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem-cell transplant. The trial did not meet the primary endpoint of superiority in progression-free survival (PFS) (median PFS 22.3 months for KMP versus 22.1 months for VMP, HR = 0.91, 95 percent CI, 0.75 - 1.10). While the data for overall survival, a secondary endpoint, are not yet mature, the observed hazard ratio (KMP versus VMP) was 1.21 (95 percent CI, 0.90 - 1.64). Neither result was statistically significant.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Carfilzomib, Kyprolis, Multiple Myeloma Patients, Hematopoietic Stem-cell Transplant, Multiple Myeloma, Clarion Trial